Samsung Biologics Profit Improves Yet Stock Undervalued: Why Samsung Biologics is rated Buy as strong margins and revenue growth persist despite labor disruption fears, leaving the stock below the average analyst target. 2026년 07월 07일 English
Kakao Stock Falls Near 52-Week Low: What Matters Kakao shares fall near 52-week lows as labor-dispute uncertainty rises, but earnings improved sharply: revenue +11.1% YoY, operating profit +66.0% YoY; analysts still rate Buy. 2026년 05월 28일 English
Samsung Biologics Quarterly Profit Jumps – Key Margin Insights Samsung Biologics is a Buy: operating profit rose 39.7% despite revenue decline, but labor disputes may create volatility until next-quarter results confirm stabilization. 2026년 05월 21일 English
Samsung Biologics Labor Unrest Fears Ease: Profit Resilience Samsung Biologics is rated Buy: labor unrest threatens production, but latest results show operating profit and net income growth despite revenue collapse, suggesting the stock’s risk discount may be excessive. 2026년 05월 05일 English
